BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 32716342)

  • 1. Serum Matrix metalloproteinase-9 (MMP-9) can help identify patients with papillary thyroid cancer at high risk of persistent disease: Value and limitations of a potential marker of neoplasia.
    Dobrescu R; Picu C; Caragheorgheopol A; Manda D; Ioachim D; Goldstein A; Badiu C
    Cancer Biomark; 2020; 29(3):337-346. PubMed ID: 32716342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early postoperative stimulated serum thyroglobulin quantifies risk of recurrence in papillary thyroid cancer.
    Jayasekara J; Jonker P; Lin JF; Engelsman AF; Wong MS; Kruijff S; Aniss A; Learoyd D; Bligh RC; Glover A; Delbridge L; Sidhu S; Sywak M
    Surgery; 2020 Jan; 167(1):40-45. PubMed ID: 31515121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between clinical and tumor features with postoperative thyroglobulin in pediatric papillary thyroid cancer.
    Tian T; Jiang L; Zhang X; Huang R; Liu B
    Surgery; 2020 Dec; 168(6):1095-1100. PubMed ID: 32948335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the 7th and 8th editions of the AJCC staging system in terms of predicting recurrence and survival in patients with papillary thyroid carcinoma.
    Nam SH; Bae MR; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2018 Dec; 87():158-164. PubMed ID: 30527232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up.
    Ahtiainen V; Vaalavirta L; Tenhunen M; Joensuu H; Mäenpää H
    Acta Oncol; 2020 Sep; 59(9):1064-1071. PubMed ID: 32603613
    [No Abstract]   [Full Text] [Related]  

  • 6. Blood prognostic predictors of treatment response for patients with papillary thyroid cancer.
    Liu X; Huang Z; He X; Zheng X; Jia Q; Tan J; Fan Y; Lou C; Meng Z
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33015713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma.
    Shi Y; Su C; Hu H; Yan H; Li W; Chen G; Xu D; Du X; Zhang P
    PLoS One; 2018; 13(6):e0198896. PubMed ID: 29949618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overall survival is improved with total thyroidectomy and radiation for male patients and patients older than 55 with T2N0M0 Stage 1 classic papillary thyroid cancer.
    MacKinney EC; Kuchta KM; Winchester DJ; Khokar AM; Holoubek SA; Moo-Young TA; Prinz RA
    Surgery; 2022 Jan; 171(1):197-202. PubMed ID: 34666913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer.
    Lin SY; Wang YY; Sheu WH
    Clin Endocrinol (Oxf); 2003 Apr; 58(4):513-8. PubMed ID: 12641636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The extent of lymph node yield in central neck dissection can be affected by preoperative and intraoperative assessment and alter the prognosis of papillary thyroid carcinoma.
    Hu JQ; Wen D; Ma B; Zhang TT; Liao T; Shi X; Wang YL; Zhu YX; Wang Y; Wei WJ; Ji QH
    Cancer Med; 2020 Feb; 9(3):1017-1024. PubMed ID: 31854077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioactive iodine does not improve overall survival for patients with aggressive variants of papillary thyroid carcinoma less than 2 cm.
    Holoubek SA; MacKinney EC; Khokar AM; Kuchta KM; Winchester DJ; Prinz RA; Moo-Young TA
    Surgery; 2022 Jan; 171(1):203-211. PubMed ID: 34384604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of matrix metalloproteinase-9 as a prognostic biomarker in papillary thyroid cancer.
    Zarkesh M; Zadeh-Vakili A; Akbarzadeh M; Fanaei SA; Hedayati M; Azizi F
    BMC Cancer; 2018 Dec; 18(1):1199. PubMed ID: 30509240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative Surveillance in Older Adults With T1N0M0 Low-risk Papillary Thyroid Cancer.
    Pradhan MC; Kazaure HS; Wang F; Zambeli-Ljepovic A; Perkins JM; Stang MT; Scheri RP
    J Surg Res; 2021 Aug; 264():37-44. PubMed ID: 33765509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
    Rosário PW; Calsolari MR
    Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
    Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Papillary Thyroid Carcinoma Recurrence: Low Yield of Neck Ultrasound With an Undetectable Serum Thyroglobulin Level.
    Epstein S; McEachern R; Khot R; Padia S; Patrie JT; Itri JN
    J Ultrasound Med; 2018 Oct; 37(10):2325-2331. PubMed ID: 29498418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphocyte-Monocyte Ratio Significantly Predicts Recurrence in Papillary Thyroid Cancer.
    Yokota M; Katoh H; Nishimiya H; Kikuchi M; Kosaka Y; Sengoku N; Watanabe M; Yamashita K
    J Surg Res; 2020 Feb; 246():535-543. PubMed ID: 31711613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eighth edition of tumor-node-metastasis staging system improve survival predictability for papillary, but not follicular thyroid carcinoma: A multicenter cohort study.
    Kim M; Kim HI; Jeon MJ; Kim HK; Kim EH; Yi HS; Kim ES; Kim H; Kim BH; Kim TY; Kim SW; Kang HC; Kim WB; Chung JH; Shong YK; Kim TH; Kim WG
    Oral Oncol; 2018 Dec; 87():97-103. PubMed ID: 30527251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
    Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
    Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence and Complications in Pediatric and Adolescent Papillary Thyroid Cancer in a High-Volume Practice.
    Rubinstein JC; Herrick-Reynolds K; Dinauer C; Morotti R; Solomon D; Callender GG; Christison-Lagay ER
    J Surg Res; 2020 May; 249():58-66. PubMed ID: 31923715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.